Evidence map›Paper›PMID 37731383›Full record

ArticleInternational journal of immunopathology and pharmacology

Down-regulation of interleukin-2 predicts poor prognosis and associated with immune escape in lung adenocarcinoma.

Yongwang Hou, Baoli Xiang, Zhicong Yang, Jiangmin Liu, Dandan Xu, Lina Geng, Minghua Zhan, Yuhuan Xu, Bin Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yongwang HouClinical Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.ORCID 0000-0001-8879-9264
Baoli XiangRespiratory Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Zhicong YangCentral Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Jiangmin LiuClinical Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Dandan XuCentral Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Lina GengClinical Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Minghua ZhanClinical Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Yuhuan XuClinical Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Bin ZhangClinical Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Hebei North University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adenocarcinoma of LungLung NeoplasmsCytokinesDown-RegulationHumansInterleukin-2PrognosisCytokinesIL2 protein, humanInterleukin-2biomarkerimmune escapeinterleukin-2lung adenocarcinoma

Identifiers

PMID37731383
PMCPMC10515527
OpenAlexW4386910279

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.